Menu
ETF
Annual · values20252024202320222021202020192018
Operating Cash Flow-3.96 M USD-12.62 M USD-6.68 M USD-6.46 M USD-6.55 M USD-2.56 M USD-609000 USD-635000 USD
Depreciation & Amortization15000 USD16000 USD15000 USD15000 USD7000 USD1000 USD
Stock-Based Compensation447000 USD310000 USD804000 USD1.39 M USD812000 USD38000 USD89000 USD
Capital Expenditures2000 USD13000 USD9000 USD6000 USD50000 USD10000 USD0 USD
Cash Flow from Investing-982000 USD-13000 USD5.99 M USD-6.01 M USD-50000 USD-10000 USD0 USD
Cash Flow from Financing3.82 M USD8.86 M USD4.62 M USD0 USD7.48 M USD17.31 M USD1.51 M USD488000 USD
Dividends Paid
Stock Buybacks
Free Cash Flow-3.96 M USD-12.63 M USD-6.69 M USD-6.46 M USD-6.60 M USD-2.57 M USD-609000 USD

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for surgical and post-operative pain management. Its core product, PRF-110, is designed as an oil-based, viscous solution applied directly into the surgical wound bed before closure to provide localized and extended analgesia. The company’s work centers on improving drug delivery in areas where sustained pain control and targeted treatment are important, particularly in hospital-based surgical settings. PainReform Ltd. operates in the healthcare and drug development sectors, where it contributes to the development of specialized treatment options built around existing active ingredients and delivery technologies. Headquartered in Israel, the company remains focused on advancing products intended for post-operative care and other clinical applications.